Institute for Global Health, University College London, London, UK.
Institute for Global Health, University College London, London, UK.
Int J Drug Policy. 2021 May;91:103101. doi: 10.1016/j.drugpo.2020.103101. Epub 2021 Jan 23.
There is little information on the prevalence of recreational drug use among UK heterosexual men and women, in particular on use of drugs associated with 'chemsex' within gay communities. The aim of this study was to examine among HIV-negative and HIV-positive heterosexual men and women in England: (i) the prevalence of recreational drug use (including use of drugs associated with chemsex), (ii) socio-economic/lifestyle correlates of drug use, and (iii) the association of drug use with sexual behavior measures and mental health symptoms.
Data are from the AURAH study of HIV-negative individuals attending sexual health clinics across England (2013-2014) and the ASTRA study of HIV-positive individuals attending HIV outpatient clinics in England (2011-2012). Prevalence of recreational drug use (past three months) and associations are presented separately among the four sample groups: HIV-negative (N = 470) and HIV-positive (N = 373) heterosexual men and HIV-negative (N = 676) and HIV-positive (N = 637) women.
The age standardized prevalence of any drug use was 22.9%, 17.1%, 15.3%, and 7.1% in the four sample groups respectively. In all groups, cannabis was the drug most commonly used (range from 4.7% to 17.9%) followed by cocaine (1.6% to 8.5%). The prevalence of use of drugs associated with chemsex was very low among HIV-negative participants (1.0% heterosexual men, 0.2% women) and zero among HIV-positive men and women. In age-adjusted analysis, factors linked to drug use overall and/or to cannabis and cocaine use specifically in the four sample groups included Black/mixed Caribbean and white (vs. Black/mixed African) ethnicity, lower level of education , cigarette smoking, and higher risk alcohol consumption. Associations of recreational drug use with measures of condomless sex, depression, and anxiety were observed in the four groups, but were particularly strong/apparent among women.
Providers need to be aware of cannabis and cocaine use and its potential link with sexual risk behavior and symptoms of depression and anxiety among heterosexual men and women attending sexual health and HIV clinics.
目前有关英国异性恋男性和女性娱乐性药物使用情况的信息很少，特别是在男同性恋群体中与“嗑药性行为”相关的药物使用情况。本研究旨在调查英格兰的 HIV 阴性和 HIV 阳性异性恋男性和女性：（i）娱乐性药物使用（包括与“嗑药性行为”相关的药物使用）的流行率，（ii）药物使用与社会经济/生活方式的关联，以及（iii）药物使用与性行为措施和心理健康症状的关联。
数据来自英格兰各地性健康诊所的 HIV 阴性个体参加的 AURAH 研究（2013-2014 年）和英格兰 HIV 门诊就诊的 HIV 阳性个体参加的 ASTRA 研究（2011-2012 年）。在四个样本组中分别介绍了娱乐性药物使用（过去三个月）和关联的流行率：HIV 阴性（N=470）和 HIV 阳性（N=373）异性恋男性以及 HIV 阴性（N=676）和 HIV 阳性（N=637）女性。
四个样本组中，药物使用的年龄标准化患病率分别为 22.9%、17.1%、15.3%和 7.1%。在所有组中，大麻是最常使用的药物（范围为 4.7%至 17.9%），其次是可卡因（1.6%至 8.5%）。在 HIV 阴性参与者中，与“嗑药性行为”相关的药物使用的患病率非常低（异性恋男性 1.0%，女性 0.2%），而 HIV 阳性男性和女性中则为零。在年龄调整分析中，与四个样本组中药物使用总体相关的因素，以及与大麻和可卡因使用具体相关的因素，包括黑人/混合加勒比和白人（而非黑人/混合非洲）种族、较低的教育水平、吸烟和较高的危险饮酒量。在四个组中观察到娱乐性药物使用与无保护性行为、抑郁和焦虑的衡量标准之间存在关联，但在女性中尤为明显/明显。
服务提供者需要意识到在性健康和 HIV 诊所就诊的异性恋男性和女性中，大麻和可卡因的使用及其与性风险行为以及抑郁和焦虑症状的潜在联系。
